Halozyme Therapeutics reported $61.86M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 762M 80.42M Jun/2025
Agios Pharmaceuticals USD 80.87M 1.91M Jun/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Amarin USD 119.52M 1.51M Mar/2025
Amgen USD 8.03B 782M Jun/2025
Baxter International USD 2.29B 530M Mar/2025
Cytokinetics USD 74.94M 863.28M Jun/2025
DBV Technologies USD 103.21M 103.21M Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Halozyme Therapeutics USD 61.86M 114.47M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
MannKind USD 57.01M 9.69M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
United Therapeutics USD 1.59B 306.8M Jun/2025